Author: GlobeNewswire

PALISADE Phase 3 clinical trials of PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD)…

OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022Enrollment nearly complete in OTO-413 Phase 2a cohort in…

NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development…

SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its upsized underwritten…

PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC, the “Company”), a biotechnology company with…

SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the…

COPENHAGEN, Denmark, Nov. 09, 2021 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology…

SUNRISE, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC, the “Company”), a biotechnology company…

EMERYVILLE, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today…

New data from 132-participant PRISM-EXT Phase 2 open-label trial show 80.3% sustained clinical cure rate through 8 weeks, with a…